UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~September~~October 1826, 2023

ARTEMIS STRATEGIC INVESTMENT CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-40855		86-1303512
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3310 East Corona Avenue

Phoenix, Arizona 85040

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (602) 346-0329

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

x¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of Class A common stock and one half of one redeemable warrant	ARTEU	The Nasdaq Stock Market LLC
Class A common stock, par value $0.0001 per share	ARTE	The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock, each	ARTEW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). ¨

~~Introductory~~Item ~~Note~~1.02 Termination of A Material Definitive Agreement

AsOn ~~previously disclosed, on August~~October 726, 2023, Artemis Strategic Investment ~~Corp.,~~Corporation ~~a Delaware corporation~~ (the “~~Artemis~~Company”), and Danam Health, Inc., amutually ~~Delaware corporation~~agreed ~~(“Danam”),~~to ~~issued~~terminate athe Agreement ~~joint~~and ~~press~~Plan ~~release~~of ~~announcing~~Merger between the ~~execution~~parties, ofdated anas ~~Agreement~~of ~~and~~August 7, ~~Plan~~2023 of(as ~~Merger, dated~~amended ~~August~~on September 7, 2023 (the “Merger Agreement”) ~~with Danam~~, ~~ASIC~~pursuant ~~Merger~~to ~~Sub Inc~~Sections 7.,1 (a) ~~Delaware corporation~~ and a7.2 ~~wholly-owned~~thereof, ~~subsidiary~~effective as of ~~the~~October ~~Company~~26, 2023 (~~“Merger~~the ~~Sub~~“Termination”),. Upon ~~Artemis~~the ~~Sponsor,~~effectiveness ~~LLC,~~of athe ~~Delaware limited liability company~~Termination, in the ~~capacity~~Merger asAgreement ~~the~~will ~~representative~~be ~~for certain stockholders~~ of ~~the~~no ~~Company,~~further force and ~~Suren Ajjarapu~~effect, inwith the ~~capacity~~exception asof the ~~representative~~specified ~~for~~provisions ~~certain~~in ~~stockholders~~Section 7.2 of ~~Danam. Pursuant to~~ the Merger Agreement, ~~and~~which ~~subject~~shall tosurvive the ~~terms~~termination ~~and conditions set forth therein, upon the consummation~~ of the ~~transactions contemplated thereby (the “Closing”),~~ Merger ~~Sub~~Agreement ~~will merge with~~ and ~~into~~remain ~~Danam,~~in full ~~with~~force ~~Danam~~and ~~surviving~~effect asin aaccordance ~~wholly-owned subsidiary of the Company (~~with ~~the~~their ~~transactions~~respective ~~contemplated by the Closing referred to as the “Transaction”)~~terms.

Item 78.01 ~~Regulation~~Other ~~FD Disclosure.~~Events

OnThe ~~September~~Company will not be able to consummate an initial business combination by November 184, 2023 (as extended from October 4, ~~Artemis~~2023 ~~issued~~for a ~~press~~period ~~release~~of one month, by the Company’s Board of Directors (the “~~Press Release~~Board”)) ~~announcing~~ (the ~~public~~“completion ~~filing~~window”), ~~with~~and pursuant to the ~~U.S.~~Company’s ~~Securities~~third amended and ~~Exchange~~restated ~~Commission~~certificate of incorporation, as amended, the Board has determined to (i) cease all operations except for the purpose of winding up as soon as practicable, (ii) as promptly as reasonably possible redeem the shares of Class A common stock that were included in the units issued in the Company’s initial public offering (the “~~SEC~~Public Shares”), at a per-share price, payable in cash, equal to the aggregate amount then on ~~September 8~~deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our taxes (less up to $100,000 ~~2023~~of interest to pay dissolution expenses), divided by the number of ~~Artemis~~outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights ~~registration~~as ~~statement~~stockholders on(including ~~Form~~the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) ~~S-4~~as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and its Board, dissolve and liquidate, subject in ~~connection~~each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the ~~Transaction~~Company’s warrants, which will expire worthless if it fails to complete its initial business combination by the end of the completion window.

A‌In ~~copy~~order to provide for the disbursement of funds from the ~~Press~~Company’s ~~Release~~trust isaccount, ~~furnished~~on asOctober ~~Exhibit~~26, 2023, the Company instructed Continental Stock Transfer ~~99.1~~& Trust Company (“Continental”), as its trustee, to ~~this~~take all necessary ~~Current~~actions ~~Report~~to onliquidate ~~Form 8-K~~the securities held in the trust account. The ~~Press~~proceeds ~~Release~~thereof, isless ~~intended~~$100,000 of interest to bepay ~~furnished~~dissolution expenses and ~~shall~~less ~~not~~net of taxes payable, will be ~~deemed~~held ~~“filed”~~in ~~for~~a ~~purposes of~~trust ~~Section 18~~operating ofaccount ~~the~~while ~~Securities~~awaiting ~~Exchange~~disbursement ~~Act~~to the holders of ~~1934,~~the Company’s asClass A ~~amended~~common stock (the “~~Exchange~~Redemption ~~Act~~Amount”),. orAll ~~otherwise~~other ~~subject~~costs and expenses associated with toimplementing the ~~liabilities~~Company’s plan of ~~that~~dissolution ~~section,~~will ~~nor~~be ~~shall~~funded itfrom beproceeds ~~deemed~~held ~~incorporated~~outside of the trust account. Record holders will receive their pro rata portion of the proceeds of the trust account by ~~reference~~delivering intheir ~~any~~Public ~~filing~~Shares ~~under~~to Continental, the Company’s ~~Securities~~transfer ~~Act~~agent. Beneficial owners of ~~1933~~Public Shares held in “street name,” ~~as amended~~however, orwill not need to take any action in order to receive the ~~Exchange~~Redemption ~~Act,~~Amount. ~~except~~The asRedemption ~~expressly~~Amount ~~set~~is ~~forth~~expected byto ~~specific~~be ~~reference~~paid inout ~~such~~within ~~filing~~ten business days after October 26, 2023.

~~Additional~~The ~~Information~~ Company intends to file a Form 15 with the Securities and ~~Where~~Exchange Commission to ~~Find~~suspend Itits reporting obligations under Sections 13 and 15(d) of the Exchange Act.

InOn ~~connection with the Merger Agreement and the Transaction, Artemis has filed with the SEC a Registration Statement on Form~~October ~~S-4~~30, ~~which includes a preliminary prospectus for registration~~2023, ofthe ~~Artemis~~Company ~~securities~~issued ~~and~~ a ~~preliminary~~press ~~proxy~~release ~~statement~~announcing ~~for Artemis’ stockholders (~~the ~~“Registration~~Termination ~~Statement”). The Registration Statement has not been declared effective by the SEC. Promptly after~~ and ~~subject to~~ the ~~Registration Statement being declared effective by the SEC, Artemis will mail the definitive proxy statement and a proxy card to its shareholders~~liquidation. ~~Investors~~A ~~and~~copy ~~securityholders~~ of ~~Artemis and other interested persons are advised to read, when available,~~ the ~~preliminary~~press ~~proxy~~release ~~statement~~is toattached be filed with the SEC, and amendments thereto, and the definitive proxy statement in connection with Artemis’ solicitation of proxies for the special meeting to be held to approve the Merger Agreement and Transaction and other documents filed in connection with the proposed Transaction because these documents will contain important information about Danam, Artemis, the combined company following the consummation of the Transaction (“Danam Health”), the Merger Agreement and the Transaction. The definitive proxy statement will be mailed to shareholders of Artemis as ~~of a record date to be established in the future for voting on the Merger Agreement and the Transaction~~Exhibit 99. ~~The~~1 ~~Registration Statement, including the definitive proxy statement, the preliminary proxy statement~~ and ~~other~~incorporated ~~relevant materials in connection with the Transaction (when they become available), and any other documents filed by Artemis with the SEC, may be obtained free of charge at the SEC's website (www~~herein.~~sec.gov) or by writing to: Artemis Strategic Investment Corporation, 3310 East Corona Avenue, Phoenix, AZ 89040, Attention: Mr. Philip N. Kaplan.~~

~~Participants~~Item in9.01 ~~the Solicitation~~Financial Statements and Exhibits.

Artemis, Danam Health, Danam and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Artemis’ stockholders with respect to the Transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the Transaction of Artemis’ directors and officers in Artemis’ filings with the SEC, including, when filed with the SEC, the Registration Statement, including its preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, amendments and supplements thereto, and other documents filed with the SEC. Such information with respect to Danam and Danam Health’s directors and executive officers will also be included in the proxy statement/prospectus. You may obtain free copies of these documents as described in the preceding paragraph.(d) Exhibits

No Offer or Solicitation

Exhibit No.		Description

10.1		Mutual Termination Agreement, dated October 26, 2023, by and between Artemis Strategic Investment Corporation and Danam Health, Inc.
99.1		Press Release, dated October 30, 2023.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

This Form 8-K is not a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the Transaction and will not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.SIGNATURE

~~Forward-Looking~~Pursuant ~~Statements~~to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~This~~ARTEMIS ~~Form 8-K~~STRATEGIC ~~contains~~INVESTMENT certain statements that are not historical facts and are forward-looking statements within the meaning of the federal securities laws with respect to the Transaction between Artemis and Danam Health, including without limitation statements regarding the anticipated benefits of the Transaction, the anticipated timing of the Transaction, the implied enterprise value, future financial condition and performance of Danam Health and the combined company after the closing and expected financial impacts of the Transaction, the satisfaction of closing conditions to the Transaction, the level of redemptions of Artemis’ public stockholders and the product candidates, products, markets, and expected future performance and market opportunities of Danam and Danam HealthCORP. ~~These~~By: ~~forward-looking~~/s/ ~~statements~~Philip ~~generally~~Kaplan ~~are~~Name: ~~identified~~Philip byKaplan ~~the words~~Title: “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “think,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “seeks,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forwardCo-~~looking.~~Chief ~~Forward-looking~~Executive ~~statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.~~Officer

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited toDated: ~~(i) the~~October ~~risk that the Transaction may not be completed in a timely manner or at all~~30, which may adversely affect the price of Artemis’ securities; (ii) the risk that the Transaction may not be completed by Artemis’ business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the Transaction, including the approval of the Merger Agreement by the stockholders of Artemis, the satisfaction of the minimum cash at closing requirements and the receipt of certain governmental, regulatory and third party approvals; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (v) the failure to achieve the minimum amount of cash available following any redemptions by Artemis’ stockholders; (vi) redemptions exceeding anticipated levels or the failure to meet Nasdaq initial listing standards in connection with the consummation of the Transaction; (vii) the effect of the announcement or pendency of the Transaction on Danam Health’s business relationships, operating results, and business generally; (viii) risks that the Transaction disrupts current plans and operations of Danam Health; (ix) the outcome of any legal proceedings that may be instituted against Danam Health or against Artemis related to the Merger Agreement or the Transaction ; (x) changes in the markets in which Danam Health competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (xi) changes in domestic and global general economic conditions; (xii) the risk that Danam Health may not be able to execute its growth strategies; (xiii) risk that Danam Health may not be able to develop and maintain effective internal controls; (xiv) costs related to the Transaction and the failure to realize anticipated benefits of the Transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xv) the ability to recognize the anticipated benefits of the Transaction and to achieve its commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Danam Health to grow and manage growth economically and hire and retain key employees; (xvi) the risk that Danam Health may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (xvii) risks related to the ability to develop, license or acquire new therapeutics; (xviii) the risk that Danam Health will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xix) the risk that Danam Health, post-combination, experiences difficulties in managing its growth and expanding operations; (xx) the risk of product liability or regulatory lawsuits or proceedings relating to Danam Health’s business; (xxi) uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; (xxii) risks associated with intellectual property protection; (xxiii) the risk that Danam Health is unable to secure or protect its intellectual property; and (xxiv) Danam Health’s limited operating history; (xxv) uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; (xxvi) risks related to regulatory review and approval and commercial development; and (xxvii) those factors discussed in Artemis’ filings with the SEC and that are contained in the proxy statement/prospectus relating to the Transaction.2023

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that will be described in the “Risk Factors” section of the Registration Statement’s proxy statement/prospectus and the amendments thereto, the definitive proxy statement/prospectus, and other documents to be filed by Artemis from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and while Danam and Artemis may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. None of Danam, Danam Health or Artemis gives any assurance that Danam Health or Artemis, or the combined company, will achieve its expectations. These forward-looking statements should not be relied upon as representing Danam Health’s, Danam’s or Artemis’ assessments as of any date subsequent to the date of this Form 8-K. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Item 9.01 Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated September 18, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARTEMIS STRATEGIC INVESTMENT CORP. By: /s/ Philip Kaplan Name: Philip Kaplan Title: Co-Chief Executive Officer

Dated: September 18, 2023

Filing Compare · Artemis Strategic Investment Corp